Literature DB >> 9307760

Acidosis in severe childhood malaria.

M English1, R Sauerwein, C Waruiru, M Mosobo, J Obiero, B Lowe, K Marsh.   

Abstract

Data were prospectively collected on 306 Kenyan children, including blood gases in 258 (75%). Severe malaria caused a predominantly high-anion-gap metabolic acidosis in at least 43% of children. Children with coma and respiratory distress (CM + RD) had greater evidence of renal dysfunction, lower mean pH and higher mean plasma osmolality than those with respiratory distress (RD) or coma (CM) as isolated findings (mean urea 10.7 vs. 6.0 vs. 4.3 mmol/l; mean creatinine 97 vs. 74 vs. 58 mumol/l; mean osmolality 301 vs. 288 vs. 283 mosmol/l; and mean pH 7.16 vs. 7.29 vs. 7.39, respectively, p < 0.001 for each comparison of CM + RD vs. RD or CM). In addition, children with CM + RD had a higher mean blood lactate (6.7 vs. 3.3 mmol/l, p < 0.001), a lower mean haemoglobin (5.5 vs. 7.0 g/dl, p = 0.002) and a lower mean age (26.4 vs. 41.9 months, p < 0.001) than children with CM and accounted for 15/24 (63%) of all deaths. These and previous data implicate hypovolaemia and renal impairment in the pathogenesis of metabolic acidosis in severe childhood malaria. In children who are acidotic, anaemia is strongly associated with lactic acidaemia and may therefore contribute to its pathogenesis. These data also imply that coma in acidotic children (CM + RD) and those with an isolated encephalopathy (CM) may result from quite different pathophysiological mechanisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307760     DOI: 10.1093/qjmed/90.4.263

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  35 in total

1.  Abnormal blood glucose concentrations on admission to a rural Kenyan district hospital: prevalence and outcome.

Authors:  F H A Osier; J A Berkley; A Ross; F Sanderson; S Mohammed; C R J C Newton
Journal:  Arch Dis Child       Date:  2003-07       Impact factor: 3.791

Review 2.  Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Authors:  Peter Winstanley; Stephen Ward; Robert Snow; Alasdair Breckenridge
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

3.  Impairment of functional capillary density but not oxygen delivery in the hamster window chamber during severe experimental malaria.

Authors:  Judith Martini; Irene Gramaglia; Marcos Intaglietta; Henri C van der Heyde
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

4.  Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions.

Authors:  B R Ogutu; C R J C Newton; J Crawley; S N Muchohi; G O Otieno; G Edwards; K Marsh; G O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

5.  Characterisation of metabolic acidosis in Kenyan children admitted to hospital for acute non-surgical conditions.

Authors:  P Sasi; M English; J Berkley; B Lowe; M Shebe; R Mwakesi; G Kokwaro
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-10-27       Impact factor: 2.184

6.  Diagnosing and treating attentional difficulties: a nationwide survey.

Authors:  I McKenzie; C Wurr
Journal:  Arch Dis Child       Date:  2004-10       Impact factor: 3.791

7.  Capillary refill: prognostic value in Kenyan children.

Authors:  A Pamba; K Maitland
Journal:  Arch Dis Child       Date:  2004-10       Impact factor: 3.791

Review 8.  Management of severe malaria.

Authors:  Tanu Singhal
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

9.  Using malarial retinopathy to improve the classification of children with cerebral malaria.

Authors:  Susan Lewallen; Rachel N Bronzan; Nicholas A Beare; Simon P Harding; Malcolm E Molyneux; Terrie E Taylor
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-08-28       Impact factor: 2.184

Review 10.  Cerebral malaria--clinical manifestations and pathogenesis.

Authors:  Rachna Hora; Payal Kapoor; Kirandeep Kaur Thind; Prakash Chandra Mishra
Journal:  Metab Brain Dis       Date:  2016-01-08       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.